Ligand Pharmaceuticals logo

Ligand Pharmaceuticals

LGND | NASDAQ
Chart Builder DCF Calculator
$293.42
+$3.35 (+1.15%)
Sep 22, 2026, 2:04 PM ET · Market open

Company Profile

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Key Executives

Name Position
Scott Plesha Chief Executive Officer of Pelthos Therapeutics
Todd C. Davis Chief Executive Officer & Director
Andrew T. Reardon Chief Legal Officer & Secretary
Octavio Espinoza Chief Financial Officer
Karen R. Reeves Senior Vice President of Investments & Head of Clinical Strategy
Keith Marschke Senior Vice President of Biology & Scientific Affairs
Marjorie Fackovec Head of People Operations
Melanie J. Herman Executive Director of Investor Relations and Financial Planning & Analysis
Paul J. Hadden Senior Vice President of Investments & Business Development
Richard Baxter Senior VP of Investment Operations
Vincent D. Antle Senior Vice President of Technical Operations & QA - Capitsol

Latest SEC Filings

Date Type Title
Sep 02, 2026 8-K/A [Amend] Current Report
Aug 14, 2026 4 Filing
Aug 14, 2026 4 Filing
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 07, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 04, 2026 4 Filing
Jul 22, 2026 S-8 Filing
Jul 14, 2026 8-K Current Report
Jul 06, 2026 4 Filing
View All SEC Filings
Ligand Pharmaceuticals
Ligand Pharmaceuticals logo
Country United States
IPO Date Nov 17, 1992
Industry Biotechnology
Sector Healthcare
Employees 47
CEO Todd C. Davis

Contact Details

555 Heritage Drive Jupiter, Florida 33458 United States

Stock Details

Ticker Symbol LGND
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000886163
CUSIP Number 53220K504
ISIN Number US53220K5048
SIC Code 2834

© 2026 bestshares.com. All rights reserved.